Abstract: A method for the manufacture an infant formula or an infant nutritional product comprising mixture of human milk oligosaccharides is disclosed. The method involves the catalytic hydrogenolysis of compounds of the general formula 1 and 2 with particular oligosaccharide profiles.

Abstract: Crystalline difucosyllactose, useful in a pharmaceutical composition and a nutritional composition, is disclosed.

Abstract: The invention provides engineered enzymes of transsialidase and/or sialyl transferase activity that have increased regioselectivity and/or increased thermostability.

Abstract: The invention relates to a mixture of human milk oligosaccharides that consists essentially of: a) a component A which is 3-FL or DFL, a component B which is LNT, LNnT, LNFP-I or 2?-FL, a component C, which is LNFP-II when component B is LNT, or LNFP-III when component B is LNnT, or LNDFH-I when component B is LNFP-I, or DFL when component B is 2?-FL, and a component D, which is lactose when component A is 3-FL, or 2?-FL when component A is DFL, with the proviso that if component B is 2?-FL, then component A is 3-FL; or consists essentially of: b) 3-FL, a component E which is LNT, LNnT or LNFP-I, and a component F, which is LNFP-II when component E is LNT, or LNFP-III when component E is LNnT, or LNDFH-I when component E is LNFP-I, and to processes for producing them and their uses.

Abstract: Mutated fucosidases are provided demonstrating improved properties in terms of thermal stability and transfucosidase synthetic performance compared with a wild type transfucosidase isolated from Bifidobacterium longum subsp. infantis.

Abstract: The application discloses a method for producing an oligosaccharide of at least four monosaccharide units, advantageously an HMO, particularly an HMO of only four monosaccharide units, said method comprising a step of: culturing, in a culture medium containing a fucosylated, sialylated or N-acetyl-glucosaminylated lactose trisaccharide as acceptor, a genetically modified cell having a recombinant gene that encodes an enzyme capable of modifying said acceptor or one of the necessary intermediates in the biosynthetic pathway of the oligosaccharide of at least four monosaccharide units, advantageously an HMO, particularly an HMO of only four monosaccharide units, from said acceptor.

Abstract: The invention relates to a mixture of human milk oligosaccharides that consists essentially of: a) a component A which is 3-FL or DFL, a component B which is LNT, LNnT, LNFP-I or 2?-FL, a component C, which is LNFP-II when component B is LNT, or LNFP-III when component B is LNnT, or LNDFH-I when component B is LNFP-I, or DFL when component B is 2?-FL, and a component D, which is lactose when component A is 3-FL, or 2?-FL when component A is DFL, with the proviso that if component B is 2?-FL, then component A is 3-FL; or consists essentially of: b) 3-FL, a component E which is LNT, LNnT or LNFP-I, and a component F, which is LNFP-II when component E is LNT, or LNFP-III when component E is LNnT, or LNDFH-I when component E is LNFP-I, and to processes for producing them and their uses.

Abstract: An achemo-enzymatic synthesis of oligosaccharides of formula 1 is presented wherein R is selected from —OH, —N 3 and —OR 6 wherein R 6 is selected from allyl optionally substituted by one or more methyl, propargyl optionally substituted by one or more methyl, 2-trimethylsilyl-ethyl, —(CH 2) n —NH 2 and —(CH 2) n —N 3 wherein integer n is to 10, preferably 2 or 3, R is selected from sialyl moiety, —SO 3 H and —CH(R)—COOH wherein R is selected from H, alkyl and benzyl, R 2 is selected from H and fucosyl, R 3 is selected from H and sialyl, R 4 is selected from H and fucosyl, provided that at least one of R 3 and R 4 is H, and A is a divalent carbohydrate linker, having important biological activities and significant commercial value for the pharmaceutical and food industry.

Abstract: The invention provides engineered enzymes of transsialidase and/or sialyl transferase activity that have increased regioselectivity and/or increased thermostability.

Abstract: A mixture of human milk oligosaccharides that consists essentially of 6?-SL, LNnT and LSTc, made by treating 6?-SL and LNnT in the presence of an ?2,6-transsialidase.

Abstract: A method of diversification of human milk oligosaccharides (HMOs) or precursors thereof, compounds obtainable by the method, and uses and compositions involving such compounds. The method comprises a) providing at least one compound or a mixture of the compounds selected from the group consisting of: optionally sialylated and/or fucosylated lactose derivatives of general formula 2 and salts thereof; b) adding at least one enzyme comprising a transglycosidase activity to the at least one compound or a mixture of compounds provided according to step a); and c) incubating the mixture obtained according to step b).

Abstract: A mixture of human milk oligosaccharides that consists essentially of 3?-O-sialyllactose, a component A which is either 3-O-fucosyllactose or lacto-N-tetraose, a component B which is 3-O-fucosyl-3?-O-sialyllactose when component A is 3-O-fucosyllactose and sialyllacto-N-tetraose a, when component A is lacto-N-tetraose and optionally lactose as a fourth component. The mixtures are made by treating 3?-O-sialyllactose and component A with an ?2,3-transsialidase. The mixtures are for use in anti-bacterial and anti-viral compositions, and for promoting the development of Bifidobacterium and Barnesiella.

Abstract: The present application discloses a method of making a mixture of 2?-FL and DFL in high yield by culturing, with lactose, a genetically modified cell having a recombinant gene that encodes a single fucosyl transferase. The resulting mixture of 2?-FL and DFL can be subjected to hydrolysis initiated by an acid or mediated by a fucosidase to produce fucose in high yields.

Abstract: The present application discloses a method for enhancing the stability of a human milk oligosaccharide (HMO) or a HMO precursor or a HMO blend when stored for extended periods at temperatures above 25° C. by spray-drying an aqueous solution of the HMO or HMO precursor to remove at least 90% of the water and providing a HMO or a HMO precursor or a HMO blend with a specific glass transition temperature. Also disclosed is a method for removing organic solvent residues from a human milk oligosaccharide (HMO) or a HMO precursor or a HMO blend by spray drying. Also disclosed is a method of enhancing the bioavailability of a human milk oligosaccharide (HMO) or a HMO precursor or a HMO blend by spray drying.

Abstract: The invention relates to a method for selective crystallization of 2?-FL from an aqueous solution comprising 2?-FL and one or more other fucosylated carbohydrates by adding acetic acid to the solution.

Abstract: Crystalline 3-O-fucosyllactose, useful in a pharmaceutical composition and a nutritional formulation, is disclosed.

Abstract: Crystalline difucosyllactose, useful in a pharmaceutical composition and a nutritional composition, is disclosed.

Abstract: The invention relates to a method for producing a glycoconjugate comprising an oligosaccharide part covalently linked to a non-sugar moiety selected from the group consisting of amino acids, peptides, proteins, lipids, longer alkyl groups, polyethylene glycols, ?,?-unsaturated amido group and polyvinyl alcohols, using a genetically modified cell.

Abstract: A crystalline LNnT polymorph IV, characterized in that it displays X-ray powder diffraction reflections, based on a measurement using CuK? radiation, at 8.16, 15.41, 39.14, 23.77, 7.77 and 31.15 2? angles, and a crystalline LNnT polymorph V, characterized in that it displays X-ray powder diffraction reflections, based on a measurement using CuK? radiation, at 9.15, 10.26, 19.68, 26.06, 20.61 and 1 1.89 2? angles, are provided.

Abstract: The invention relates to a mixture of human milk oligosaccharides that consists essentially of: a) a component A which is 3-FL or DFL, a component B which is LNT, LNnT, LNFP-I or 2?-FL, a component C, which is LNFP-II when component B is LNT, or LNFP-III when component B is LNnT, or LNDFH-I when component B is LNFP-I, or DFL when component B is 2?-FL, and a component D, which is lactose when component A is 3-FL, or 2?-FL when component A is DFL, with the proviso that if component B is 2?-FL, then component A is 3-FL; or consists essentially of: b) 3-FL, a component E which is LNT, LNnT or LNFP-I, and a component F, which is LNFP-II when component E is LNT, or LNFP-III when component E is LNnT, or LNDFH-I when component E is LNFP-I, and to processes for producing them and their uses.